|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus : An open-label, prospective, randomized, parallel-group comparison trial
This item is licensed under:Creative Commons Attribution-NonCommercial 4.0 International
Title: | Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus : An open-label, prospective, randomized, parallel-group comparison trial |
Authors: | Cho, Kyu Yong Browse this author | Nakamura, Akinobu Browse this author →KAKEN DB | Omori, Kazuno Browse this author | Takase, Takahiro Browse this author | Miya, Aika Browse this author | Manda, Naoki Browse this author | Kurihara, Yoshio Browse this author | Aoki, Shin Browse this author | Atsumi, Tatsuya Browse this author →KAKEN DB | Miyoshi, Hideaki Browse this author →KAKEN DB |
Keywords: | body weight control | cardiovascular disease | randomized trial | SGLT2 inhibitor | thiazolidinediones | type 2 diabetes |
Issue Date: | Mar-2019 |
Publisher: | Wiley |
Journal Title: | Diabetes, Obesity and Metabolism |
Volume: | 21 |
Issue: | 3 |
Start Page: | 710 |
End Page: | 714 |
Publisher DOI: | 10.1111/dom.13557 |
Abstract: | The effects of dapagliflozin (DAP) and pioglitazone (PIO) on body weight and glycaemic control were compared in patients with type 2 diabetes mellitus. Seventy-one patients on PIO were either switched to DAP (n = 36) at 5 mg per day or continued on PIO (n = 35). Primary endpoints were superiority of body weight loss and non-inferiority of HbA1c level after 24 weeks with DAP. Body weight decrease was greater with DAP than with PIO (75.3 ± 14.9 to 71.3 ± 15.1 kg vs. 74.7 ± 13.8 to 75.2 ± 13.9 kg; P < 0.01). Change in the HbA1c level was comparable (P = 0.64). The level of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and urinary albumin : creatinine ratio (ACR) decreased only with DAP (NT-proBNP, P < 0.01; ACR, P = 0.02), and the change in NT-proBNP correlated negatively with baseline NT-proBNP level (ρ = -0.68, P < 0.01) and log-converted ACR (ρ = -0.35, P < 0.05). DAP promotes body weight loss in type 2 diabetes mellitus and may decrease fluid retention, thus reducing the occurrence of cardiovascular events. |
Rights: | http://creativecommons.org/licenses/by-nc/4.0/ |
Type: | article |
URI: | http://hdl.handle.net/2115/72905 |
Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 三好 秀明
|